Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.47 |
| ▸ | MDM4 | O15151 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14111048 | 1.00 | TLR2 (0.59) | TLR2EPHX2KMT2ASIRT5SIRT2 | |
| SCHEMBL14110980 | 0.92 | TLR2 (0.57) | TLR2EPHX2KMT2AMDM2PLG | |
| SCHEMBL14596250 | 0.92 | TLR2 (0.57) | TLR2EPHX2KMT2AMDM2PLG | |
| SCHEMBL10143538 | 0.89 | TLR2 (0.54) | TLR2SIRT5SIRT2SIRT1 | |
| SCHEMBL20833861 | 0.89 | TLR2 (0.63) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL15715832 | 0.89 | TLR2 (0.63) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL4600387 | 0.89 | TLR2 (0.54) | TLR2EPHX2KMT2AMDM2 | |
| SCHEMBL4600383 | 0.89 | TLR2 (0.54) | TLR2EPHX2KMT2AMDM2 | |
| SCHEMBL31212512 | 0.88 | TLR2 (0.59) | TLR2KMT2AMDM2MDM4TP53 | |
| SCHEMBL29746167 | 0.88 | TLR2 (0.61) | TLR2KMT2AMDM2MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | TLR2 2757/4885EPHX2 1731/4885KMT2A 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.